Metrikler
Yayın
133
Açık Erişim
9
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
2010 - 2013
2010 - 2013Tıpta Yandal Uzmanlık
İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye
2002 - 2006
2002 - 2006Tıpta Uzmanlık
İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Türkiye
1996 - 2002
1996 - 2002Lisans
İstanbul Üniversitesi-Cerrahpaşa, Cerrahpaşa Tıp Fakültesi, Türkiye
Araştırma Alanları
Sağlık Bilimleri
Akademik Faaliyetlere Dayalı Araştırma Alanları
Avesis Araştırma Alanları
WoS Araştırma Alanları
Scopus Araştırma Alanları
Akademik Ünvanlar / Görevler
2022 - Devam Ediyor
2022 - Devam EdiyorProf. Dr.
Acıbadem Mehmet Ali Aydınlar Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
2010 - 2013
2010 - 2013Araştırma Görevlisi
İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
2002 - 2006
2002 - 2006Araştırma Görevlisi
İstanbul Üniversitesi, Dahili Tıp Bilimleri Bölümü
Yönetilen Tezler
2019
2019Tıpta Uzmanlık
Mide kanserinde MSI-H ile MSI-H ekspresyonu sıklığı ve klinikopatolojik parametreler ve sağ kalımla ilişkisi
Yıldız İ. (Danışman)
Ş.BAHŞİ(Öğrenci)
Makaleler
Tümü (88)
SCI-E, SSCI, AHCI (74)
SCI-E, SSCI, AHCI, ESCI (85)
ESCI (7)
Scopus (81)
TRDizin (5)
Diğer Yayınlar (2)
2026
20261. Evolving Concepts and Contemporary Management of Early-Stage Breast Cancer: An Evidence-Based Approach to Grey Zones from a Comprehensive Breast Unit Part 2: Systemic Treatment
Şenocak Taşçı E., SÖNMEZ Ö., OYAN ULUÇ B., KORKMAZ T., YILDIZ İ., Bozkurt M., et al.
European Journal of Breast Health
, cilt.22, sa.1, ss.1-18, 2026 (ESCI, Scopus, TRDizin)
2025
20252. Next-generation sequencing-based genomic profiling of advanced soft tissue and bone sarcomas
Gündoğdu Y., Şenocak Taşçı E., Özer L., Boynukara C., Çeçen R., Mutlu A. U., et al.
Frontiers in Oncology
, cilt.15, 2025 (SCI-Expanded, Scopus)
2024
20243. Total Neoadjuvant Therapy Versus Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: A Multi-Institutional Real-World Study
Şenocak Taşçı E., Mutlu A. U., Saylık O., Ölmez Ö. F., Bilici A., Sünger E., et al.
Cancers
, cilt.16, sa.18, 2024 (SCI-Expanded, Scopus)
2024
20244. Contemporary results from the PelvEx collaborative: improvements in surgical outcomes for locally advanced and recurrent rectal cancer
Fahy M., Kelly M. E., Abecasis N., Akhtar S. N., Akiyoshi T., Alvarez-Gallego M., et al.
COLORECTAL DISEASE
, sa.5, ss.926-931, 2024 (SCI-Expanded, Scopus)
2024
20245. Efficacy of adjuvant capecitabine in residual triple negative breast cancer: a multicenter observational Turkish Oncology Group (TOG) study
Tasci E. S., KUTLU Y., ÖLMEZ Ö. F., Mutlu A. U., Gundogdu Y., Seyyar M., et al.
EXPERT OPINION ON PHARMACOTHERAPY
, cilt.25, sa.4, ss.477-484, 2024 (SCI-Expanded)
2023
20236. The safety and efficacy of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma: A multicenter real-world study from Turkey
AKYILDIZ A., Guven D. C., Ozluk A. A., Ismayilov R., Mutlu E., Unal O. U., et al.
MEDICINE
, cilt.102, sa.45, 2023 (SCI-Expanded, Scopus)
2023
20237. Discrepancy among microsatellite instability detection methodologies in non-colorectal cancer: Report of 3 cases
Tasci E. S., Yildiz İ., Erdamar S., Ozer L.
WORLD JOURNAL OF CLINICAL CASES
, sa.13, ss.3105-3113, 2023 (SCI-Expanded, Scopus)
2023
20238. Omitting hemicolectomy for patients with appendiceal neuroendocrine tumours of 1–2 cm
Aktas M. K., AYTAÇ E., YILDIZ İ., OZER L.
The Lancet Oncology
, cilt.24, sa.5, 2023 (SCI-Expanded, Scopus)
2023
20239. Current trends in perioperative treatment of resectable gastric cancer.
Yıldız İ., Özer L., Şenocak Taşçı E., Bayoglu İ. V., Aytac E.
World journal of gastrointestinal surgery
, cilt.15, sa.3, ss.323-337, 2023 (SCI-Expanded)
2023
202310. Impact of Professional Seniority on Total Neoadjuvant Treatment Approach for Locally Advanced Rectal Cancer
Şenocak Taşçi E., AYTAÇ E., Ajredini M., Mutlu A. U., YILDIZ İ., OZER L.
Journal of Oncological Science
, cilt.9, sa.2, ss.89-96, 2023 (Scopus, TRDizin)
2022
202211. Intramural Component of Venous, Lymphatic, and Perineural Invasion in Colon Cancer: A Threat or an Illusion?
Özer L., Taşçı E. Ş., Mutlu A. U., Piyade B., Ramoğlu N., Ajredini M., et al.
BALKAN MEDICAL JOURNAL
, cilt.39, sa.6, ss.436-443, 2022 (SCI-Expanded, Scopus)
2021
202112. Tailored total neoadjuvant therapy for locally advanced rectal cancer: One size may not fit for all!
Ozer L., Yıldız İ., Bayoglu V., Bozkurt M., Esen E., Remzi F. H., et al.
COLORECTAL DISEASE
, cilt.23, sa.7, ss.1662-1669, 2021 (SCI-Expanded, Scopus)
2021
202113. Clinicopathological and Prognostic Significance of MSI Status and PD-L1 Expression in Turkish Patients with Gastric Cancer
Bahsi S., YILDIZ İ., Erdamar S., Goksel S., Tozun N., AYTAÇ E., et al.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.31, sa.4, ss.246-254, 2021 (SCI-Expanded, Scopus)
2021
202114. Liver and Pancreatic Injury in Response to ALK Inhibitors in a Patient with Primary Signet Ring Cell Carcinoma of the Lung: A Case Report
YILDIZ İ.
CASE REPORTS IN ONCOLOGY
, cilt.14, sa.1, ss.107-111, 2021 (Hakemli Dergi)
2020
202015. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., et al.
LUNG CANCER
, cilt.148, ss.48-54, 2020 (SCI-Expanded, Scopus)
2019
201916. Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Kilickap S., Demirci U., Bugdayci F., Tural D., KORKMAZ T., PAYDAŞ S., et al.
JOURNAL OF THORACIC ONCOLOGY
, sa.10, 2019 (SCI-Expanded, Scopus)
2019
201917. PDL-1 expression is poor prognostic factor in gastric carcinomas?
Erdamar S., Bahsi S., YILDIZ İ.
VIRCHOWS ARCHIV
, cilt.475, 2019 (SCI-Expanded, Scopus)
2019
201918. Dealing with the gray zones in the management of gastric cancer: The consensus statement of the Istanbul Group
AYTAÇ E., Aslan F., ÇİÇEK B., Erdamar S., Gurses B., GÜVEN K., et al.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.30, sa.7, ss.584-598, 2019 (SCI-Expanded, Scopus, TRDizin)
2018
201819. Prognostic factors for survival in metastatic renal cell carcinoma patients with brain metastases receiving targeted therapy.
Yildiz İ., Bilici A., Karadurmus N., Ozer L., Tural D., Kaplan M. A., et al.
Tumori
, cilt.104, sa.6, ss.444-450, 2018 (SCI-Expanded, Scopus)
2018
201820. The role of FOLFOXIRI in chemorefractory metastatic colorectal cancer patients
Yıldız İ.
JOURNAL of ONCOLOGICAL SCIENCES
, cilt.4, sa.1, ss.60-61, 2018 (Hakemli Dergi)
2017
201721. Is Change in Hemoglobin Level a Predictive Biomarker of Tyrosine Kinase Efficacy in Metastatic Renal Cell Carcinoma? A Turkish Oncology Group Study
Bilir C., Yildiz İ., Bilici A., Ucar M., Berk V., Yildiz Y., et al.
CANCER INVESTIGATION
, cilt.35, sa.4, ss.248-255, 2017 (SCI-Expanded, Scopus)
2017
201722. SERUM LEVELS OF OMENTIN-1 IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER: THE IZMIR ONCOLOGY GROUP (IZOG) STUDY
Yildiz Y., KÜÇÜKZEYBEK Y., ALACACIOĞLU A., Taskaynatan H., YILDIZ İ., Varol U., et al.
ACTA MEDICA MEDITERRANEA
, cilt.33, sa.4, ss.549-555, 2017 (SCI-Expanded, Scopus)
2017
201723. THE EFFECTS OF ADJUVANT CHEMOTHERAPY ON SERUM ADMA AND ENDOTHELIN-1 LEVELS IN EARLY STAGE BREAST CANCER PATIENTS ( IZMIR ONCOLOGY GROUP (IZOG) STUDY
Akyol M., Kara M., Alacacioglu A., Demir L., ELLİDOKUZ H., Kucukzeybek Y., et al.
ACTA MEDICA MEDITERRANEA
, cilt.33, sa.4, ss.557-564, 2017 (SCI-Expanded, Scopus)
2017
201724. Prognostic value of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with epithelial ovarian cancer
Yildiz Y., Kucukzeybek Y., Alacacioglu A., Varol U., Yildiz İ., Akyol M., et al.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY
, cilt.38, sa.3, ss.444-448, 2017 (SCI-Expanded, Scopus)
2016
201625. Alteration of thyroid functions in patients with renalcell carcinoma treated with tyrosine kinaseinhibitors Turkish population study
BİLİR C., YILDIZ İ., BİLİCİ A., UÇAR M., BERK V., YILDIZ Y., et al.
Journal of Human Rhythm , cilt.2, sa.4, ss.144-148, 2016 (Hakemli Dergi)
2016
201626. Outcome of Patients With Metastatic Chromophobe Renal Cell Carcinoma Treated With Sunitinib
Keizman D., Sarid D., Lee J. L., Sella A., Gottfried M., Hammers H., et al.
ONCOLOGIST
, cilt.21, sa.10, ss.1212-1217, 2016 (SCI-Expanded, Scopus)
2016
201627. Current adjuvant treatment modalities for gastric cancer: From history to the future
Kilic L., Ordu C., Yildiz İ., Sen F., Keskin S., Ciftci R., et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
, cilt.8, sa.5, ss.439-449, 2016 (SCI-Expanded, Scopus)
2016
201628. Same Chemotherapy Regimen Leads to Different Myelotoxicity in Different Malignancies: A Comparison of Chemotherapy-Associated Myelotoxicity in Patients With Advanced Ovarian and Non-Small-Cell Lung Cancer
TAŞ F., YILDIZ İ., Kilic L., Ciftci R., Keskin S., Sen F.
AMERICAN JOURNAL OF THERAPEUTICS
, cilt.23, sa.3, 2016 (SCI-Expanded, Scopus)
2016
201629. Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
Ordu C., Pilanci K. N., Avci N., YILDIZ İ., Alco G., Demirhan O., et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
, cilt.20, sa.2, ss.147-152, 2016 (ESCI, Scopus)
2015
201530. The increased transglutaminase 2 expression levels during initial tumorigenesis predict increased risk of metastasis and decreased disease-free and cancer-specific survivals in renal cell carcinoma
ERDEM S., YEGEN G., Telci D., YILDIZ İ., TEFIK T., İŞSEVER H., et al.
WORLD JOURNAL OF UROLOGY
, cilt.33, sa.10, ss.1553-1560, 2015 (SCI-Expanded, Scopus)
2015
201531. Frequency of EGFR Mutation in Nsclc and Its Relationship with Clinicopathological Features: A Multicenter Asmo Trial
Yuksel S., Kodaz H., Yildiz İ., Odabasi H., Ocak A., Bayoglu I. V., et al.
JOURNAL OF THORACIC ONCOLOGY
, cilt.10, sa.9, 2015 (SCI-Expanded, Scopus)
2015
201532. Quality of life in colorectal cancer patients: an Izmir Oncology Group (IZOG) study.
Akyol M., Ulger E., Alacacioglu A., Kucukzeybek Y., Bayoglu V., Yildiz Y., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.20, sa.4, ss.1015-22, 2015 (SCI-Expanded, Scopus)
2015
201533. Evaluation of c-kit (CD 117) expression as a prognostic factor in testicular germ cell tumors: an Izmir Oncology Group (IZOG) study.
Salman T., Yildiz E., Yildiz İ., Yavuzer D., Unlu M., Varol U., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.20, sa.4, ss.1054-60, 2015 (SCI-Expanded, Scopus)
2015
201534. Sexual satisfaction, anxiety, depression and quality of life among Turkish colorectal cancer patients [Izmir Oncology Group (IZOG) study]
Akyol M., Ulger E., Alacacioglu A., Kucukzeybek Y., Yildiz Y., Bayoglu V., et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
, cilt.45, sa.7, ss.657-664, 2015 (SCI-Expanded, SSCI, Scopus)
2015
201535. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.
Vedat Bayoglu I., Yildiz İ., Varol U., Cokmert S., Kucukzeybek Y., Alacacioglu A., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.20, sa.2, ss.460-7, 2015 (SCI-Expanded, Scopus)
2015
201536. Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers
Bayoglu I. V., Kucukzeybek B. B., Kucukzeybek Y., Varol U., Yildiz İ., Alacacioglu A., et al.
BIOMEDICINE & PHARMACOTHERAPY
, cilt.70, ss.190-195, 2015 (SCI-Expanded, Scopus)
2015
201537. Diagnostic value of serum M30 and M65 in patients with nasopharyngeal carcinoma
Sen F., Yildiz İ., Odabas H., Tambas M., Kilic L., Karadeniz A., et al.
TUMOR BIOLOGY
, cilt.36, sa.2, ss.1039-1044, 2015 (SCI-Expanded, Scopus)
2015
201538. The Effects of Adjuvant Endocrine Treatment on Serum Leptin, Serum Adiponectin and Body Composition in Patients with Breast Cancer: The Izmir Oncology Group (IZOG) Study
Akyol M., Demir L., Alacacioglu A., ELLİDOKUZ H., Kucukzeybek Y., Yildiz Y., et al.
CHEMOTHERAPY
, cilt.61, sa.2, ss.57-64, 2015 (SCI-Expanded, Scopus)
2015
201539. Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study
Bayoglu I. V., Yildiz İ., Varol U., Cokmert S., Alacacioglu A., Kucukzeybek Y., et al.
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
, cilt.19, sa.5, ss.385-390, 2015 (ESCI, Scopus)
2015
201540. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients
Kilic L., YILDIZ İ., Sen F. K., Erdem M. G., SERİLMEZ M., Keskin S., et al.
CANCER BIOMARKERS
, cilt.15, sa.4, ss.405-411, 2015 (SCI-Expanded, Scopus)
2015
201541. Adjuvant chemotherapy and prognostic factors in stage II colon cancer - Izmir oncology group study
Kucukzeybek Y., Dirican A., Demir L., Yildirim S., Akyol M., Yildiz Y., et al.
Asian Pacific Journal of Cancer Prevention
, cilt.16, sa.6, ss.2413-2418, 2015 (SCI-Expanded, Scopus)
2014
201442. Cardiac tamponade in a patient treated by sunitinib for metastatic renal cell carcinoma.
Yildiz İ., Varol U., Sen F., Kilic L.
Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology
, cilt.14, sa.7, ss.654-6, 2014 (SCI-Expanded, Scopus, TRDizin)
2014
201443. Assessment of the Quality of Life in Turkish Breast Cancer Patients
Yildiz İ., Varol U., Alacacioglu A.
JOURNAL OF BREAST HEALTH
, cilt.10, sa.4, ss.216-221, 2014 (ESCI)
2014
201444. Gastric cancer with diffuse hepatic metastases and complete radiological response to triplet chemotherapy
Varol U., Alacacioglu A., Yildiz İ., Kucukzeybek Y., Uslu R.
JOURNAL OF BUON
, cilt.19, sa.4, ss.1128-1129, 2014 (SCI-Expanded, Scopus)
2014
201445. Clinical significance of serum M30 and M65 levels in patients with breast cancer
TAŞ F., KARABULUT S., YILDIZ İ., DURANYILDIZ H. D.
BIOMEDICINE & PHARMACOTHERAPY
, cilt.68, sa.8, ss.1135-1140, 2014 (SCI-Expanded, Scopus)
2014
201446. Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial.
Yildiz İ., Ekenel M., Akman T., Kocar M., Uysal M., Kanitez M., et al.
Anticancer research
, cilt.34, sa.8, ss.4329-34, 2014 (SCI-Expanded, Scopus)
2014
201447. The behavior of Turkish cancer patients in fasting during the holy month of Ramadan.
TAŞ F., KARABULUT S., Ciftci R., YILDIZ İ., Keskin S., Kilic L., et al.
Japanese journal of clinical oncology
, cilt.44, sa.8, ss.705-10, 2014 (SCI-Expanded, Scopus)
2014
201448. Sexual satisfaction, anxiety, depression and quality of life in testicular cancer survivors
Alacacioglu A., Ulger E., Varol U., YAVUZŞEN T., Akyol M., Yildiz Y., et al.
MEDICAL ONCOLOGY
, cilt.31, sa.7, 2014 (SCI-Expanded, SSCI, Scopus)
2014
201449. High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer.
Ciftci R., TAŞ F., TİLGEN YASASEVER C., Aksit E., KARABULUT S., Sen F., et al.
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
, cilt.35, sa.7, ss.6941-8, 2014 (SCI-Expanded, Scopus)
2014
201450. Markers to predict the efficacy of bevacizumab in the treatment of metastatic colorectal cancer
Varol U., Yildiz İ., Salman T., KARABULUT B., Uslu R.
TUMORI J
, cilt.100, sa.4, ss.370-376, 2014 (SCI-Expanded, Scopus)
2014
201451. Is there any diagnostic value of serum protease-activated receptor-1 (PAR1) levels on determination of epithelial ovarian carcinoma?
Karabulut S., Aksit E., Tas F., Ciftci R., Aydiner A., Yildiz İ., et al.
TUMOR BIOLOGY
, cilt.35, sa.5, ss.4323-4329, 2014 (SCI-Expanded, Scopus)
2014
201452. Survival and prognostic factors in adult patients with recurrent or refractory ewing sarcoma family tumours: a 13-years retrospective study in Turkey.
Yildiz İ., Sen F., Ekenel M., Darendeliler E., Bavbek S., Agaoglu F., et al.
In vivo (Athens, Greece)
, cilt.28, sa.3, ss.403-9, 2014 (SCI-Expanded, Scopus)
2014
201453. Second-Line Capecitabine and Oxaliplatin Combination for Gemcitabine-Resistant Advanced Pancreatic Cancer
Bayoglu I. V., Varol U., Yildiz İ., Muslu U., Alacacioglu A., Kucukzeybek Y., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.15, sa.17, ss.7119-7123, 2014 (SCI-Expanded, Scopus)
2014
201454. Depression, Anxiety and Sexual Satisfaction in Breast Cancer Patients and their Partners-Izmir Oncology Group Study
Alacacioglu A., Ulger E., Varol U., Yildiz İ., Salman T., Bayoglu V., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.15, sa.24, ss.10631-10636, 2014 (SCI-Expanded, Scopus)
2014
201455. Intolerance to sunitinib treatment in hemodialysis patients with metastatic renal cell carcinoma.
YILDIZ İ., Sen F., Kilic L., Ciftci R., BAŞARAN M.
Korean journal of urology
, cilt.55, sa.1, ss.74-6, 2014 (Hakemli Dergi)
2014
201456. Survival Analysis of Triple Negative and Her2 Positive Breast Cancer Patients: Single Center Report
Varol U., ÇAKAR B., Yildiz İ., TUNAKAN DALGIÇ C., ÖZIŞIK H., Ozisik M., et al.
JOURNAL OF BREAST HEALTH
, cilt.10, sa.1, ss.42-46, 2014 (Hakemli Dergi)
2014
201457. Isolated Liver Metastasis of Sacrococcygeal Chordoma: Case Report and Review of the Literature
Akyol M., Varol U., Yildiz İ., Bayoglu I. V., Yildiz Y., Demir L., et al.
CASE REPORTS IN ONCOLOGICAL MEDICINE
, cilt.2014, 2014 (ESCI)
2014
201458. First-Line Mono-Chemotherapy in Frail Elderly Patients with Metastatic Colorectal Cancer
Varol U., Dirican A., Yildiz İ., Oktay E., Degirmenci M., Alacacioglu A., et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.15, sa.7, ss.3157-3161, 2014 (SCI-Expanded, Scopus)
2014
201459. Quality-of-Life in Turkish Cancer Patients: The Impact of Sociodemographic Characteristics, Medical History, and Management
Toptas T., Yildiz İ., YILDIZ M., Varol U., Bayoglu I. V., Ozguroglip M.
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI
, cilt.24, sa.1, ss.23-29, 2014 (SCI-Expanded, Scopus, TRDizin)
2014
201460. A case of non-Hodgkin lymphoma coexisting with both hepatitis B and tuberculosis
Yildiz İ., Varol U., Varol Y., BAŞARAN M.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY
, cilt.29, sa.2, ss.53-56, 2014 (ESCI, Scopus)
2014
201461. Anticancer Therapy for Breast Cancer Patients with Skin Metastases Refractory to Conventional Treatments
Varol U., Yildiz İ., Alacacioglu A., Uslu R.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.15, sa.4, ss.1885-1887, 2014 (SCI-Expanded, Scopus)
2013
201362. Prognostic factors associated with the response to sunitinib in patients with metastatic renal cell carcinoma
Yildiz İ., Sen F., Kilic L., Ekenel M., Ordu C., Kilicaslan I., et al.
CURRENT ONCOLOGY
, cilt.20, sa.6, 2013 (SCI-Expanded, Scopus)
2013
201363. Clinical significance of serum M30 and M65 levels in metastatic pancreatic adenocarcinoma
TAŞ F., KARABULUT S., Bilgin E., Sen F., YILDIZ İ., TAŞTEKİN D., et al.
TUMOR BIOLOGY
, cilt.34, sa.6, ss.3529-3536, 2013 (SCI-Expanded, Scopus)
2013
201364. The Role of Surgical Methods in the Treatment of Anorectal Malignant Melanoma (AMM)
Keskin S., Tas F., Karabulut S., Yildiz İ., Kilic L., Ciftci R., et al.
ACTA CHIRURGICA BELGICA
, cilt.113, sa.6, ss.429-433, 2013 (SCI-Expanded, Scopus)
2013
201365. Clinical significance of serum M30 and M65 levels in melanoma
TAŞ F., KARABULUT S., SERİLMEZ M., YILDIZ İ., Sen F., Ciftci R., et al.
MELANOMA RESEARCH
, cilt.23, sa.5, ss.390-395, 2013 (SCI-Expanded, Scopus)
2013
201366. Performance status of patients is the major prognostic factor at all stages of pancreatic cancer.
TAŞ F., Sen F., Odabas H., Kilic L., Keskin S., YILDIZ İ.
International journal of clinical oncology
, cilt.18, sa.5, ss.839-46, 2013 (SCI-Expanded, Scopus)
2013
201367. Serum M65 as a biomarker for metastatic renal cell carcinoma.
YILDIZ İ., Sen F., Kilic L., Keskin S., DURANYILDIZ H. D., Bilgin E., et al.
Clinical genitourinary cancer
, cilt.11, sa.3, ss.290-6, 2013 (SCI-Expanded, Scopus)
2013
201368. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer
Yildiz İ., Tas F., Kilic L., Sen F., Saip P., Eralp Y., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, cilt.72, sa.2, ss.437-444, 2013 (SCI-Expanded, Scopus)
2013
201369. Prognostic factors in metastatic pancreatic cancer: Older patients are associated with reduced overall survival.
TAŞ F., Sen F., Keskin S., Kilic L., YILDIZ İ.
Molecular and clinical oncology
, cilt.1, sa.4, ss.788-792, 2013 (Hakemli Dergi)
2013
201370. Biweekly triplet chemotherapy with gemcitabine, cisplatin and vinorelbine for advanced chemotherapy naive non-small cell lung cancer
Keskin S., TAŞ F., EKENEL M., Kilic L., Sen F., YILDIZ İ., et al.
TUMORI
, cilt.99, sa.4, ss.463-468, 2013 (SCI-Expanded, Scopus)
2013
201371. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.
Sen F., Yildiz İ., Başaran M., Ekenel M., Oz F., Kilic L., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.18, sa.3, ss.775-81, 2013 (SCI-Expanded, Scopus)
2013
201372. Modified DCF (mDCF) regimen seems to be as effective as original DCF in advanced gastric cancer (AGC).
Keskin S., YILDIZ İ., AYDOĞMUŞ ŞEN F., AYDOĞAN F., Kilic L., EKENEL M., et al.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
, cilt.15, sa.5, ss.403-8, 2013 (SCI-Expanded, Scopus)
2013
201373. Patterns of Complementary and Alternative Medicine Use among Turkish Cancer Patients
YILDIZ İ., Ozguroglu M., TOPTAŞ T., TURNA Z. H., Sen F., YILDIZ M.
JOURNAL OF PALLIATIVE MEDICINE
, cilt.16, sa.4, ss.383-390, 2013 (SCI-Expanded, Scopus)
2013
201374. Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients.
Aydiner A., Kilic L., Yildiz İ., Keskin S., Sen F., Kucucuk S., et al.
Medical oncology (Northwood, London, England)
, cilt.30, sa.1, ss.354, 2013 (SCI-Expanded, Scopus)
2013
201375. Clinical and prognostic significance of coagulation assays in advanced epithelial ovarian cancer.
TAŞ F., Kilic L., Bilgin E., Keskin S., Sen F., Ciftci R., et al.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
, cilt.23, sa.2, ss.276-81, 2013 (SCI-Expanded, Scopus)
2013
201376. Clinical Outcomes and Prognostic Factors Associated with the Response to Erlotinib in Non-Small-Cell Lung Cancer Patients with Unknown EGFR Mutational Status
Aydiner A., Yildiz İ., Seyidova A.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION
, cilt.14, sa.5, ss.3255-3261, 2013 (SCI-Expanded, Scopus)
2013
201377. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.
Aykan N. F., Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., et al.
Medical oncology (Northwood, London, England)
, cilt.30, sa.3, ss.679, 2013 (SCI-Expanded, Scopus)
2013
201378. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients?
Kilic L., Ordu C., EKENEL M., YILDIZ İ., Keskin S., Sen F., et al.
Medical oncology (Northwood, London, England)
, cilt.30, sa.3, ss.660, 2013 (SCI-Expanded, Scopus)
2012
201279. Clinical and prognostic significance of coagulation assays in melanoma.
TAŞ F., Ciftci R., Kilic L., Bilgin E., Keskin S., Sen F., et al.
Melanoma research
, cilt.22, sa.5, ss.368-75, 2012 (SCI-Expanded, Scopus)
2012
201280. Primary Burkitt's Lymphoma Presenting as a Rapidly Growing Thyroid Mass
YILDIZ İ., Sen F., Toz B., Kilic L., Agan M., BAŞARAN M.
CASE REPORTS IN ONCOLOGY
, cilt.5, sa.2, ss.388-393, 2012 (ESCI, Scopus)
2011
201181. Response rates and adverse effects of continuous once-daily sunitinib in patients with advanced renal cell carcinoma: a single-center study in Turkey.
Yildiz İ., Sen F., Basaran M., Ekenel M., Agaoglu F., Darendeliler E., et al.
Japanese journal of clinical oncology
, cilt.41, sa.12, ss.1380-7, 2011 (SCI-Expanded, Scopus)
2011
201182. Triplet chemotherapy combination with gemcitabine, cisplatin, and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer
TAŞ F., Sen F., Guney N., Yildiz İ., Camlica H., Keskin S., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)
2011
201183. Impaired coronary flow reserve in patients with metastatic cancer treated with sunitinib.
Sen F., Yildiz İ., Oflaz H., Oz F., Kilic L., Gurdal A., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)
2011
201184. Triplet chemotherapy combination with gemcitabine, cisplatin, and docetaxel in patients with chemotherapy-naive advanced non-small cell lung cancer
TAŞ F., Sen F., Guney N., Yildiz İ., Camlica H., Keskin S., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)
2011
201185. Frequency of cardiovascular events in patients with metastatic renal cell carcinoma under sunitinib treatment.
Yildiz İ., Sen F., BAŞARAN M., Bavbek S. E.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.29, sa.15, 2011 (SCI-Expanded, Scopus)
2011
201186. Noncutaneous melanoma have distinct features from each other and cutaneous melanoma.
TAŞ F., Keskin S., Karadeniz A., Dagoglu N., Sen F., Kilic L., et al.
Oncology
, cilt.81, sa.5-6, ss.353-8, 2011 (SCI-Expanded, Scopus)
2011
201187. Optic disc and choroidal metastasis from sporadic medullary thyroid carcinoma: case report and review of the literature.
Yildiz İ., Sen F., Tuncer S., Kilic L., Basaran M., Bavbek S.
Onkologie
, cilt.34, sa.11, ss.630-3, 2011 (SCI-Expanded, Scopus)
2009
200988. An unusual case of recurrent non-Hodgkin's lymphoma presented with massive ascites, peritoneal involvement and elevated CA-125 level
Doventas A., YILDIZ İ., TOPTAŞ T., Baslar Z., Bilici A., ERDİNÇLER Ü. D.
JOURNAL OF BUON
, cilt.14, sa.2, ss.324-325, 2009 (SCI-Expanded, Scopus)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2022
20221. The prognostic impact of intramural invasion in patients undergoing surgery for non-metastatic colon cancer.
Ozer L., Tasci E. S., Mutlu A. U., Piyade B., Ramoglu N., Ajredini M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)
2022
20222. The professional seniority affects the clinical application of total neoadjuvant therapy for locally advanced rectal cancer.
Tasci E. S., AYTAÇ E., Ajredini M., Mutlu A. U., Yildiz İ., Ozer L.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, (Özet Bildiri)
2019
20193. Clinicopathological and prognostic significance of microsatellit instability (MSI) status and PDI-1 expression in Turkish patients with gastric cancer.
Yildiz İ., Bahsi S., Erdamar S., Goksel S., Demir G., Er Ö., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri)
2016
20164. Sexual satisfaction, anxiety, depression and quality of life amoung Turkish gynecological cancer patients
Yildiz Y., Akyol M., Alacacioglu A., Kucukzeybek Y., Asik N., Taskaynatan H., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri)
2016
20165. Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib
Neiman V., Keizman D., Sarid D., Lee J., Sella A., Gottfried M., et al.
41st Annual Congress of the European-Society-for-Medical-Oncology (ESMO), Copenhagen, Danimarka, 7 - 11 Ekim 2016, cilt.27, (Özet Bildiri)
2016
20166. Thrombin activatable fibrinolysis inhibitor, tissue factor pathway inhibitor, and prothrombin fragment 1+2 levels in patients with advanced colorectal cancer.
Salman T., Bilici A., Arslan C., Varol U., Yildiz İ., Akyol M., et al.
Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 21 - 23 Ocak 2016, cilt.34, (Özet Bildiri)
2016
20167. Evaluation of c-kit (CD 117) expression as a prognostic factor in testicular germ cell tumors: An Izmir Oncology Group (IZOG) study.
Salman T., Yildiz E., Yildiz İ., Yavuzer D., Unlu M., Varol U., et al.
Genitourinary Cancers Symposium, San-Francisco, Kostarika, 7 - 09 Ocak 2016, cilt.34, (Özet Bildiri)
2015
20158. The effects of adjuvant endocrine treatment on the serum leptin, adiponectin and body composition in patients with breast cancer [Izmir Oncology Group(IZOG) Study]
Akyol M., Demir L., Alacacioglu A., Ellidiokuz H., Kucukzeybekl Y., Yildiz Y., et al.
European Cancer Congress, Vienna, Avusturya, 01 Ocak 2015, cilt.51, (Özet Bildiri)
2015
20159. First-line cisplatin plus bolus 5-Fluorouracil combination in patients with locally advanced and metastatic esophageal cancer
Akyol M., Kucukzeybek Y., Varol U., Yildiz İ., Cokmert S., Bayoglu I. V., et al.
ESMO 17th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 1 - 04 Temmuz 2015, cilt.26, (Özet Bildiri)
2015
201510. Can basal neutrophil/lymphocytes ratio predict clinical outcome of melanoma patients?
Bayoglu I. V., Kurtel G., Alacacioglu A., Varim C., Yildiz İ., Kucukzeybek Y., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201511. Patients (pts) with metastatic chromophobe renal cell carcinoma (mchRCC) treated with sunitinib (Su) therapy (tx): Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC)
Yildiz İ., Sarid D., Lee J., Chish A., Sella A., Gottfried M., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri)
2015
201512. Patients with metastatic chromophobe renal cell carcinoma treated with sunitinib therapy: Analysis of an international database regarding outcome and comparison to clear cell histology (mccRCC).
Keizman D., Sarid D., Lee J., Gottfried M., Maimon N., Hammers H. J., et al.
Genitourinary Cancers Symposium, Florida, Amerika Birleşik Devletleri, 26 - 28 Şubat 2015, cilt.33, (Özet Bildiri)
2014
201413. Clinical significance of serum macrophage migration inhibitory factor (MIF) level in breast cancer.
Ciftci R., TAŞ F., Aksit E., VATANSEVER S., KARABULUT S., Sen F., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
201414. Sunitinib in patients with metastatic non-clear renal cell carcinoma: A multicentric retpospective Turkish Oncology Group (TOG) trial.
Yildiz İ., EKENEL M., Altman T., Kocar M., Uysal M., Kanitez M., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri)
2014
201415. Clinical significance of serum protein and mRNA level of insulin-like growth factor-1 (IGF-1) in patients with hepatocellular carcinoma
KARABULUT S., Aykan N. F., Yildiz İ., Kilic L., Sen F., VATANSEVER S.
Gastrointestinal Cancers Symposium, San-Francisco, Kostarika, 16 - 18 Ocak 2014, cilt.32, (Özet Bildiri)
2013
201316. Coagulation assays in breast cancer: Correlation of plasma D-dimer with tumor load and invasiveness in breast cancer patients.
KARABULUT S., Kilic L., Ciftci R., Yildiz İ., Sen F., Keskin S., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201317. Effect of increased body mass index on time to tumor progression in metastatic unresectable colorectal cancer patients treated with bevacizumab-based therapy
Yildiz İ., Sen F., Kilic L., Keskin S., Ciftci R., EKENEL M., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201318. Comparison of mucosal and cutaneous melanoma in the head and neck region: Different clinical features and similar outcomes.
Ciftci R., Keskin S., KARABULUT S., Yildiz İ., Kilic L., Sen F., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2013
201319. Is there any prognostic importance of pretreatment serum M30 and serum M65 levels on progression-free survival of patients with metastatic renal cell carcinoma treated with first-line sunitinib?
BAŞARAN M., Yildiz İ., Sen F., Kilic L., Keskin S., Darendeliler E., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2013, cilt.31, (Özet Bildiri)
2006
200620. Imatinib meylate response in gastrointestinal stromal tumors Experience of Cerrahpasa Medical Faculty
YILDIZ İ., MANDEL N. K., DEMİR O. G., ÖZGÜROĞLU M., TOPTAŞ T., BÜYÜKÜNAL E., et al.
31st ESMO Congress, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.164
2006
200621. Erdheim-Chester disease: Report of a case
Yildiz İ., Mandel N. M., Dervisoglu S., Toptas T.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.210, (Özet Bildiri)
2006
200622. Imatinib mesylate response in Gastrointestinal Stromal Tumors: Experience of cerrahpasa medical faculty
Yildiz İ., Mandel N. M., Demir G., Ozguroglu M., Toptas T., Buyukunal E., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.164, (Özet Bildiri)
Kitaplar
2019
20191. Adjuvant Systemic Therapy: Endocrine Therapy
Yıldız İ.
Breast Disease, Adnan Aydiner Abdullah İğci Atilla Soran, Editör, Springer-Verlag , Zürich, ss.103-127, 2019
2019
20192. Adjuvant Endocrine Therapy for Breast Cancer
Yıldız İ., Aydiner A.
Breast Cancer : A Guide to Clinical Practice, Adnan AydinerAbdullah IgciAtilla Soran, Editör, Springer, London/Berlin , London, ss.413-432, 2019
2016
20163. Adjuvant Endocrine Therapy
Yıldız İ.
Breast Disease: Management and Therapies, Adnan Aydiner,Atilla Soran,Abdullah İgci, Editör, Springer, London/Berlin , Basel, ss.99-130, 2016
Desteklenen Projeler
2023 - 2025
2023 - 2025Yüksek Riskli Evre II-IV Melanom Bulunan Gönüllülerde Adjuvan Plasebo Artı Pembrolizumaba Kıyasla Adjuvan V940 (mRNA-4157) Artı Pembrolizumabın Değerlendirildiği Randomize, Çift Kör, Plasebo ve Aktif Komparatör Kontrollü Faz 3 Klinik Çalışma”
Diğer Ülkelerdeki Özel Organizasyonlar Tarafından Desteklenmiş Proje
Yıldız İ. (Yürütücü)
2023 - 2025
2023 - 2025A Phase 3, Randomized Study to Evaluate the Efficacy and Safety ofPembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma
Diğer Ülkelerdeki Özel Organizasyonlar Tarafından Desteklenmiş Proje
Yıldız İ.
Bilimsel Kuruluşlardaki Üyelikler / Görevler
2020 - Devam Ediyor
2020 - Devam EdiyorASCO
Asli Üye
2019 - Devam Ediyor
2019 - Devam EdiyorESMO
Asli Üye
2010 - Devam Ediyor
2010 - Devam EdiyorTürk Tibbi Onkoloji Derneği
Asli Üye
Bilimsel Yayınlarda Hakemlikler
Temmuz 2015
Temmuz 2015ANNALS OF ONCOLOGY
SCI Kapsamındaki Dergi
Ödüller
Haziran 2012
Haziran 2012Sunitinib ile tedavi edilen metastatik kanserli hastalarda koroner akım rezervinin degerlendirilmesi
Türk Tibbi Onkoloji Derneği
Kongre ve Sempozyum Katılımı Faaliyetleri
24 Nisan 2024 - 28 Mayıs 2025
24 Nisan 2024 - 28 Mayıs 2025Türk Tibbi Onkoloji Kongresi
Davetli Konuşmacı
Girne-Kıbrıs (Kktc)
26 Nisan 2023 - 30 Nisan 2023
26 Nisan 2023 - 30 Nisan 202310.Türk Tibbi Onkoloji Kongresi
Davetli Konuşmacı
Antalya-Türkiye
13 Nisan 2023 - 16 Nisan 2023
13 Nisan 2023 - 16 Nisan 2023Hedef Kanser
Panelist
Girne-Kıbrıs (Kktc)
17 Mart 2023 - 19 Mart 2023
17 Mart 2023 - 19 Mart 2023AVOD Onkoloji Günleri
Davetli Konuşmacı
Eskişehir-Türkiye
18 Mayıs 2022 - 22 Mayıs 2022
18 Mayıs 2022 - 22 Mayıs 20229.Türk Tibbi Onkoloji Kongresi
Moderatör
Girne-Kıbrıs (Kktc)
21 Nisan 2022 - 24 Nisan 2022
21 Nisan 2022 - 24 Nisan 2022Hedef Kanser 2022
Panelist
Girne-Kıbrıs (Kktc)
03 Kasım 2021 - 07 Kasım 2021
03 Kasım 2021 - 07 Kasım 20218. Türk Tıbbi Onkoloji Kongresi
Moderatör
Antalya-Türkiye
Atıflar
Toplam Atıf Sayısı (SCOPUS): 652
h-indeksi (SCOPUS): 14
Jüri Üyelikleri
Ekim-2025
Ekim 2025Akademik Kadroya Atama-Doçentlik
Doçentlik Sınav Jürisi, Üniversitelerarası Kurul, Ekim 2025 - Acıbadem Mehmet Ali Aydınlar Üniversitesi
Mart-2024
Mart 2024Akademik Kadroya Atama-Profesörlük
Akademik Kadroya Atama-Profesörlük - Acıbadem Mehmet Ali Aydınlar Üniversitesi
Ekim-2023
Ekim 2023Akademik Kadroya Atama-Doçentlik
Doçentlik Sınav Jürisi, Üniversitelerarası Kurul, Ekim 2023 - Acıbadem Mehmet Ali Aydınlar Üniversitesi
Ekim-2023
Ekim 2023Akademik Kadroya Atama-Doçentlik
Doçentlik Sınav Jürisi, Üniversitelerarası Kurul, Ekim 2023 - Acıbadem Mehmet Ali Aydınlar Üniversitesi
Ekim-2023
Ekim 2023